- Home
- MEIP vs PWM Comparison
MEIP vs PWM Comparison
Compare MEIP & PWM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MEIP
- PWM
- Stock Information
- Founded
- MEIP 2000
- PWM 2018
- Country
- MEIP United States
- PWM Hong Kong
- Employees
- MEIP N/A
- PWM N/A
- Industry
- MEIP Biotechnology: Pharmaceutical Preparations
- PWM
- Sector
- MEIP Health Care
- PWM
- Exchange
- MEIP Nasdaq
- PWM Nasdaq
- Market Cap
- MEIP 13.3M
- PWM 13.3M
- IPO Year
- MEIP 2003
- PWM 2023
- Fundamental
- Price
- MEIP $2.18
- PWM $0.40
- Analyst Decision
- MEIP Hold
- PWM
- Analyst Count
- MEIP 1
- PWM 0
- Target Price
- MEIP N/A
- PWM N/A
- AVG Volume (30 Days)
- MEIP 6.4K
- PWM 84.3K
- Earning Date
- MEIP 05-13-2025
- PWM 06-17-2025
- Dividend Yield
- MEIP N/A
- PWM N/A
- EPS Growth
- MEIP N/A
- PWM N/A
- EPS
- MEIP N/A
- PWM N/A
- Revenue
- MEIP N/A
- PWM $639,912.00
- Revenue This Year
- MEIP N/A
- PWM N/A
- Revenue Next Year
- MEIP N/A
- PWM N/A
- P/E Ratio
- MEIP N/A
- PWM N/A
- Revenue Growth
- MEIP 33.76
- PWM N/A
- 52 Week Low
- MEIP $1.46
- PWM $0.31
- 52 Week High
- MEIP $4.10
- PWM $2.70
- Technical
- Relative Strength Index (RSI)
- MEIP 53.30
- PWM 47.64
- Support Level
- MEIP $2.05
- PWM $0.34
- Resistance Level
- MEIP $2.25
- PWM $0.43
- Average True Range (ATR)
- MEIP 0.11
- PWM 0.04
- MACD
- MEIP 0.00
- PWM -0.00
- Stochastic Oscillator
- MEIP 69.91
- PWM 36.59
About MEIP MEI Pharma Inc.
MEI Pharma Inc is focused on the clinical development of novel therapies for cancer. The company's clinical drug candidate includes Pracinostat, an orally available histone deacetylase inhibitor for the treatment of patients with acute myeloid leukemia and myelodysplastic syndrome. Its clinical development portfolio also includes Zandelisib, an oral inhibitor of phosphatidylinositide 3-kinase delta for the treatment of patients with recurrent chronic lymphocytic leukemia or follicular non-Hodgkin's lymphoma; and ME-344, an isoflavone-based mitochondrial inhibitor for the treatment of HER2-negative breast cancer and Pracinostat, an oral histone deacetylase inhibitor. Geographically, all the business activities function through the region of the United States.
About PWM Prestige Wealth Inc.
Prestige Wealth Inc is engaged in providing private wealth management services and asset management to high-net-worth and ultra-high-net-worth individuals and enterprises through its subsidiaries.